Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $59.7452W HIGH $94.75
Volume
579.39 K
Value Traded
123.33 M
Short % Float
6.77%
-0.14%Week
-2.23%1 Month
+16.08%3 Month
+24.89%6 Month
+4.1%5 Year
+7,539.04%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
5.09 B
EPS (TTM)
2.44
P/E Ratio
34.97
Ent. Value
5.38 B
Total Shares
59.74 M
Float Shares
58.16 M
Insiders
2.60%
Institutions
105.62%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
MMSI Catalyst Timeline
Dated clinical, regulatory and corporate events for Merit Medical Systems, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Merit Medical Systems, Inc.
744Total events
3Upcoming
168Tier-1 (high impact)
2007 to 2027Coverage
Upcoming catalysts 2
Event history 50
◆Oral PresentationPresentation
Merit Medical to participate in Bank of America Healthcare Conference fireside chat
▲AcquisitionCorporate
Merit acquires View Point Medical, Inc. (OneMark System) for $140M
oncologysource ↗
▲Product LaunchPost-Market
US commercial release of Resilience TTS Esophageal Stent
esophageal fistulas and strictures caused by malignant tumorssource ↗
▲AcquisitionDualCapCorporate
Merit sells DualCap product line assets to Health Line International for $28M
◆Oral PresentationPresentation
Merit Medical to present at 44th Annual J.P. Morgan Healthcare Conference
●Management ChangeCorporate
F. Ann Millner appointed Chair of the Board effective January 5, 2026
●Management ChangeCorporate
Fred P. Lampropoulos resigned as director and Chair on January 4, 2026
◆Enrollment CompleteTrial
Final enrollment expected in WRAP Global registry
hemodialysis vascular access obstructionsource ↗
▲Full ResultsClinical Data
24-month efficacy results from WRAPSODY WAVE Trial
venous outflow obstructions in hemodialysis patientssource ↗
▲Trial InitiationTrial
WRAP North America Registry initiated
venous outflow obstructions in hemodialysis patientssource ↗
▲Product LaunchPost-Market
Full U.S. commercialization of WRAPSODY CIE begins immediately
venous outflow obstructions in hemodialysis patientssource ↗
▲Oral PresentationPresentation
24-month efficacy results presented at VIVA conference
venous obstructions in arteriovenous fistula for hemodialysissource ↗
▲Full ResultsClinical Data
24-month TLPP and ACPP results from AVG cohort of WAVE trial presented at VEINS conference
arteriovenous graft stenosis or occlusion in hemodialysis patientssource ↗
●Oral PresentationPresentation
Presentation of AVG cohort results at VIVA Foundation VEINS conference
arteriovenous graft stenosis or occlusion in hemodialysis patientssource ↗
▲Partnership / LicenseCorporate
Merit Medical signs definitive asset purchase agreement to acquire C2 CryoBalloon technology from PENTAX Medical
Barrett's esophagus, gastric antral vascular ectasia (GAVE) syndromesource ↗
◆Management ChangeCorporate
Martha Aronson named new President and CEO, effective October 3, 2025
▲Quarterly UpdateSCOUTCorporate
SCOUT Radar Localization reaches 750,000 patients treated worldwide
breast cancersource ↗
◆AcquisitionCorporate
Closing of C2 CryoBalloon acquisition expected in Q4 2025
Barrett's esophagus, gastric antral vascular ectasia (GAVE) syndromesource ↗
▲EU ApprovalEx-US Regulatory
CE Mark for genicular artery embolisation to treat knee osteoarthritis
knee osteoarthritissource ↗
▲First Patient DosedTrial
First patient enrolled in WRAP North America registry
hemodialysis vascular access obstructionsource ↗
▲Product LaunchPost-Market
US commercial release of Prelude Wave Hydrophilic Sheath Introducer with SnapFix Technology
radial access proceduressource ↗
▲Quarterly UpdateCorporate
Merit Medical updates full-year 2025 guidance: net sales $1.495-$1.507B, non-GAAP EPS $3.52-$3.72
▲AcquiredCorporate
Merit Medical acquires Biolife Delaware, L.L.C., manufacturer of StatSeal and WoundSeal hemostatic devices
●Trial InitiationTrial
Initiation of WRAP North America Registry post-market study
dialysis accesssource ↗
▲Other Regulator MilestoneEx-US Regulatory
Health Canada approval of WRAPSODY CIE
hemodialysis vascular access stenosissource ↗
▲Product LaunchPost-Market
Immediate commercialization in Canada
hemodialysis vascular access stenosissource ↗
▲Full ResultsClinical Data
12-month primary patency results from WAVE trial
hemodialysis vascular access stenosissource ↗
▲Full ResultsClinical Data
12-month efficacy results from single-arm AVG cohort of WAVE trial released
arteriovenous graft (AVG) dysfunctionsource ↗
▲FDA ApprovalFDA Decision
Health Canada approval
venous obstructions in arteriovenous fistula for hemodialysissource ↗
▲Other Regulator MilestoneEx-US Regulatory
Health Canada approval for WRAPSODY CIE
arteriovenous graft stenosis or occlusion in hemodialysis patientssource ↗
▲Other Regulator MilestoneEx-US Regulatory
Health Canada approval for WRAPSODY CIE
venous outflow obstructions in hemodialysis patientssource ↗
▼Quarterly UpdateCorporate
Merit Medical updates FY2025 non-GAAP EPS guidance to $3.29-$3.42, reaffirms revenue guidance
▲Oral PresentationPresentation
12-month results from single-arm AVG cohort of WAVE trial presented at Charing Cross Symposium
arteriovenous graft (AVG) dysfunctionsource ↗
▲Product LaunchPost-Market
US commercial release of Ventrax Delivery System
ventricular tachycardia (VT)source ↗
▲Full ResultsClinical Data
6-month results of WRAPSODY CIE published in Kidney International
stenosis in venous outflow of arteriovenous fistula in hemodialysis patientssource ↗
▲Full ResultsClinical Data
12-month efficacy results of WRAPSODY CIE presented at SIR 50th Annual Scientific Meeting
stenosis in venous outflow of arteriovenous fistula in hemodialysis patientssource ↗
▲FDA ApprovalWRAPSODYApprovedFDA Decision
FDA premarket approval of Wrapsody Cell-Impermeable Endoprosthesis
dialysis patients requiring long-term vessel patencysource ↗
Past FDA Catalysts and PDUFA Decisions
How MMSI actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
No drug pipeline
Merit Medical Systems, Inc. is a medical device company. The clinical trials it takes part in test other companies' drugs, so it has no drug pipeline of its own to score.
Clinical Trial Results
Readouts, endpoints and source filings for every MMSI program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| WRAPSODY CIE | restoring vascular access in hemodialysis patients | 2025-11-05 | TLPP: 48.6% vs. 29.8%; p<0.0001; ACPP: 31.3% vs. 20.6%; p=0.003Read More | Merit Medical Releases 24-Month Efficacy Results from the Randomized Arteriovenous Fistula (AVF) Arm of the WRAPSODY Arteriovenous Access Efficacy (WAVE) TrialRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Peterson Neil W.Officer (CHIEF OPERATING OFFICER) | Sell | -7,500 18,051 held | $90.45 | 08/24/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in MMSI
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| PFM HEALTH SCIENCES, LP | 1.2 % (20 %) | 13.66 M | 197.04 K | 21.28% ( 34.57 K) |
MMSI Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2027-04-16 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How MMSI ranks across every disease it competes in
Competitive Position is a premium feature
See how MMSI ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialMMSI News
MMSI▲ +0.2%today
Merit Medical Systems to Announce Third Quarter 2026 Results on October 29, 2026
Merit Medical Systems, Inc. will announce its financial results for Q3 2026 on October 29, 2026. The announcement will occur after market close, followed by an investor conference call at 4:30 p.m. Eastern. Interested parties can pre-register for the call and access a live webcast on the company's website.
Read more →MMSIMerit Medical to Participate in Upcoming Investors Conferences in September
Merit Medical Systems, Inc. will participate in several upcoming investor conferences in September 2026. Key events include the Wells Fargo Healthcare Conference, Baird Global Healthcare Conference, and the Sidoti Small Cap Conference. Management will engage in fireside chats and 1x1 meetings, providing opportunities for investor interaction and insights into the company's operations.
Read more →MMSIMerit Medical Announces Global Operations Leadership Transition
Merit Medical Systems has announced the appointment of Sheri Lewis as Executive Vice President of Global Operations, effective August 31, 2026. With over 30 years of experience in operations and supply chain management, Lewis is expected to enhance the company's global operational excellence. Neil Peterson will transition to a Senior Advisor role to ensure a smooth handover.
Read more →MMSIMerit Medical to Participate in Upcoming Investors Conferences in August
Merit Medical Systems, Inc. will participate in two upcoming investor conferences in August 2026. The Canaccord Genuity 46th Annual Growth Conference will take place from August 11-13, where management will hold a fireside chat. Additionally, they will participate in the Bank of America SMID Cap Conference on August 12. Live webcasts of these events will be available online.
Read more →MMSIMerit Medical Systems to Announce Second Quarter 2026 Results on July 30, 2026
Merit Medical Systems, Inc. will announce its financial results for Q2 2026 on July 30, 2026, after market close. An investor conference call is scheduled for the same day at 4:30 p.m. Eastern. The company continues to engage with investors and maintain transparency regarding its financial performance.
Read more →MMSISUMMARY OF MERIT MEDICAL SYSTEMS, INC. 2026 EQUITY INCENTIVE PLAN The following is a brief description of the principal features of the Merit Medical Systems, Inc. 2026 Equity Incentive Plan (the "2026 Equity Incentive P
Merit Medical Systems, Inc. has introduced the 2026 Equity Incentive Plan designed to incentivize its directors, employees, and consultants. The plan includes various award types, such as stock options and restricted stock units, with a total reserve of 2,700,000 shares. The Compensation Committee will oversee the selection and distribution of awards. This incentive plan will take effect until May 2036, aiming to align the interests of participants with those of shareholders.
Read more →MMSIMerit Medical Shareholders Elect Scott R. Ward to Board of Directors
Merit Medical Systems, Inc. has elected Scott R. Ward to its Board of Directors for a three-year term. His extensive experience in the healthcare and medical device industry, including leadership roles at Medtronic, is expected to contribute significantly to the company's strategic priorities. Ward's appointment is viewed positively by the Board and management, highlighting his potential impact on the company's growth.
Read more →MMSIMerit Medical to Participate in the Bank of America Healthcare Conference
Merit Medical Systems, Inc. will participate in the Bank of America 2026 Health Care Conference in Las Vegas from May 12-14, 2026. The management team is scheduled for a fireside chat on May 12th at 3:00 pm PT. A live audio webcast will be available, along with a replay for 90 days post-event.
Read more →MMSI▲ +5.2%on this news
Merit Medical Reports First Quarter 2026 Results and Updates Full-Year Guidance
Merit Medical Systems, Inc. reported a strong financial performance for Q1 2026, with a revenue increase of 7% to $381.9 million. Key highlights include a GAAP EPS of $0.68, a significant rise of 39%, and improved operating margins. The company also completed a strategic divestiture and an acquisition of View Point Medical, which is anticipated to enhance its oncology product portfolio. Guidance for full-year 2026 remains optimistic, with revenue projected between $1.612 billion and $1.634 billion.
Read more →MMSI▲ +5.2%on this news
MERIT MEDICAL REPORTS FIRST QUARTER 2026 RESULTS AND UPDATES FULL-YEAR GUIDANCE
Merit Medical Systems, Inc. announced its first quarter financial results for 2026, reporting revenue growth and solid earnings. The company achieved a 3.7% increase in organic revenue, alongside improvements in operating margins and free cash flow. Merit also provided updated guidance for the year, reflecting anticipated revenue contributions from its recent acquisition of View Point Medical. Overall, the results suggest a positive trajectory for Merit in achieving its financial goals for 2026.
Read more →MMSIMerit Medical Systems to Announce First Quarter 2026 Results on April 30, 2026
Merit Medical Systems, Inc. will announce its financial results for Q1 2026 on April 30, 2026. The results will be released after market close, followed by an investor conference call at 4:30 p.m. Eastern. The company is known for its proprietary medical devices across various medical fields.
Read more →MMSIMerit Medical Acquires View Point Medical, Inc., expanding the Merit Therapeutic Oncology Portfolio
Merit Medical Systems, Inc. has acquired View Point Medical, Inc. for approximately $140 million, enhancing its therapeutic oncology portfolio. The acquisition includes the OneMark Detection Imaging System, which aids in the localization of breast and soft tissue tumors. While projected revenue growth is promising, the acquisition will initially dilute Merit’s GAAP earnings per share.
Read more →MMSIMerit Medical Launches the Resilience Through-the-Scope Esophageal Stent
Merit Medical Systems, Inc. has announced the U.S. commercial release of its Resilience Through-the-Scope Esophageal Stent, designed for treating esophageal fistulas and strictures caused by malignant tumors. This stent features proprietary anti-migration flanges to enhance stability and is available in multiple sizes to meet various clinical needs. A single-handed deployment system allows for improved control during placement. The launch signifies a significant advancement in the TTS stent technology market, aiming to enhance patient care in endoscopic procedures.
Read more →MMSIMerit Medical Reports Fourth Quarter and Full Year 2025 Results and Issues Fiscal Year 2026 Guidance
Merit Medical Systems, Inc. announced strong financial results for Q4 and FY 2025, highlighting a 6.8% organic revenue growth and improved margins. The company generated over $215 million in free cash flow, marking a 16% year-over-year increase. For FY 2026, Merit provided optimistic guidance, emphasizing confidence in ongoing operational execution despite potential risks from trade policies and acquisitions.
Read more →MMSIMERIT MEDICAL REPORTS FOURTH QUARTER AND FULL YEAR 2025 RESULTS AND ISSUES FISCAL YEAR 2026 GUIDANCE
Merit Medical Systems, Inc. announced its financial results for Q4 and fiscal year 2025, highlighting a 6.8% organic, constant currency revenue growth. The company achieved a notable increase in free cash flow, reaching over $215 million, reflecting its strong operational performance. For fiscal year 2026, Merit has introduced revenue and earnings per share guidance, indicating confidence in continued stable growth and profitability despite providing caution regarding potential external risks and uncertainties that could influence future results.
Read more →MMSIMerit Medical Appoints F. Ann Millner as Chair of the Board and Announces Projected Preliminary Unaudited Revenue Results for the Fourth Quarter of 2025
Merit Medical Systems has announced the appointment of F. Ann Millner as Chair of the Board effectively from January 5, 2026, succeeding Fred P. Lampropoulos, who resigned as a part of a leadership transition. The announcement also included preliminary unaudited revenue results for the fourth quarter of 2025, indicating a notable increase compared to the previous year. The company plans to provide full financial results and guidance for fiscal year 2026 on February 24, 2026.
Read more →MMSIMerit Medical to Participate at the J.P. Morgan Healthcare Conference
Merit Medical Systems, Inc. will participate in the 44th Annual J.P. Morgan Healthcare Conference from January 12-15, 2026. CEO Martha G. Aronson and CFO Raul Parra will present on January 13th at 4:30 PM PT. Presentation materials and a live audio webcast will be available on the company's investor relations website.
Read more →MMSIMerit Medical Provides Update on U.S. Reimbursement and Commercial Strategies for WRAPSODY Cell-Impermeable Endoprosthesis .
Merit Medical Systems has announced that the U.S. Centers for Medicare & Medicaid Services deferred its application for Transitional Pass-Through payment regarding the WRAPSODY Cell-Impermeable Endoprosthesis, with a potential effective date now set for January 2027. In response, Merit plans to adjust its commercial strategy aimed at increasing patient access while immediately starting to commercialize the device in the U.S. The company forecasts potential revenue from the WRAPSODY device ranging from $2 million to $4 million for the year 2025, supported by promising clinical efficacy data.
Read more →MMSIMerit Medical Releases 24-Month Efficacy Results from the Randomized Arteriovenous Fistula (AVF) Arm of the WRAPSODY Arteriovenous Access Efficacy (WAVE) Trial
Merit Medical Systems announced positive 24-month efficacy results from the randomized AVF arm of the WAVE trial, which evaluated the WRAPSODY CIE device for restoring vascular access in hemodialysis patients. The results showed significantly higher TLPP and ACPP rates for the WRAPSODY CIE compared to PTA. The findings were presented at the VIVA conference and indicate the device's potential to extend functional vascular access.
Read more →About Merit Medical Systems, Inc.
Headquarters1600 WEST MERIT PARK WAY, SOUTH JORDAN, UT, 84095
BIOPHARMAWATCH ELITE PLUS
Trade the next MMSI catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime